Palvella Therapeutics Inc (PVLA)

May 05, 2026

Palvella to Report Q1 Results, Host May 7 Conference Call - MyChesCo

May 05, 2026

May 04, 2026

Palvella doses first patients in angiokeratoma trial By Investing.com - Investing.com Australia

May 04, 2026

May 04, 2026

Palvella doses first patients in angiokeratoma trial - Investing.com UK

May 04, 2026

May 04, 2026

Palvella Therapeutics Announces First Patients Dosed In Phase 2 Lotu Trial Of Fast Track-Designated Qtorin™ Rapamycin For Clinically Significant Angiokeratomas - TradingView

May 04, 2026

May 04, 2026

No FDA-approved therapy exists; Palvella starts angiokeratoma study - Stock Titan

May 04, 2026

May 04, 2026

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas - Yahoo Finance Singapore

May 04, 2026

May 02, 2026

Jennison Associates LLC Has $40.56 Million Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat

May 02, 2026

May 01, 2026

Palvella Therapeutics (PVLA) Expected to Announce Quarterly Earnings on Thursday - MarketBeat

May 01, 2026

Apr 30, 2026

Palvella Thrives Ahead of Q1 Figures - Baystreet.ca

Apr 30, 2026

Apr 30, 2026

Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026 - The Globe and Mail

Apr 30, 2026

Apr 29, 2026

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Apr 29, 2026

Apr 28, 2026

Palvella Therapeutics (NASDAQ:PVLA) Shares Gap UpWhat's Next? - MarketBeat

Apr 28, 2026

Apr 27, 2026

Palvella to Present QTORIN Study Data at ISSVA 2026 Conference - MyChesCo

Apr 27, 2026

Apr 27, 2026

Deltec Asset Management LLC Has $251,000 Stock Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat

Apr 27, 2026

Apr 26, 2026

Palvella Therapeutics (PVLA) Price Target Increased by 39.58% to 115.65 - MSN

Apr 26, 2026

Apr 26, 2026

Certain Common Stock of Palvella Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-APR-2026. - marketscreener.com

Apr 26, 2026

Apr 25, 2026

New Palvella Director Brings Rare Disease Insight To Low Valued Stock - Yahoo Finance

Apr 25, 2026

Apr 24, 2026

PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) - ChartMill

Apr 24, 2026

Apr 22, 2026

PVLA (Palvella Therapeutics Inc.) posts wider than expected Q4 2025 loss, shares dip 0.69% in today’s trading.Attention Driven Stocks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026

Apr 22, 2026

Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Palvella Therapeutics (PVLA) - The Globe and Mail

Apr 22, 2026

Apr 21, 2026

Palvella Therapeutics Appoints John D. Doux to Board - MyChesCo

Apr 21, 2026

Apr 20, 2026

Palvella to present Phase 3, Phase 2 study results at ISSVA By Investing.com - Investing.com Australia

Apr 20, 2026

Apr 20, 2026

Palvella Therapeutics (PVLA) Stock Approaches Resistance (Volatility Increases) 2026-04-20Community Breakout Alerts - Xã Thanh Hà

Apr 20, 2026

Apr 20, 2026

Palvella to present Phase 3, Phase 2 study results at ISSVA - Investing.com

Apr 20, 2026

Apr 20, 2026

Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026 - Yahoo Finance

Apr 20, 2026

Apr 16, 2026

Palvella reports 2025 results, advances QTORIN drug pipeline - MSN

Apr 16, 2026

Apr 16, 2026

Palvella Therapeutics, Inc. (PVLA): Investor Outlook and 78.86% Potential Upside in Biotech Breakthroughs - DirectorsTalk Interviews

Apr 16, 2026

Apr 14, 2026

Palvella Appoints Kent Taylor as Senior Vice President of Sales - MyChesCo

Apr 14, 2026

Apr 13, 2026

Palvella Therapeutics appoints John Doux to board of directors By Investing.com - Investing.com Australia

Apr 13, 2026

Apr 13, 2026

Palvella Therapeutics, Inc. Files Form 8-K with SEC – Company Details, Address, and Key Information - Minichart

Apr 13, 2026

Apr 13, 2026

Palvella Therapeutics appoints John Doux, M.D., to board of directors By Investing.com - Investing.com South Africa

Apr 13, 2026

Apr 13, 2026

Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors - Bitget

Apr 13, 2026

Apr 13, 2026

Palvella Therapeutics appoints John Doux, M.D., to board of directors - Investing.com

Apr 13, 2026

Apr 13, 2026

Palvella Therapeutics Adds Independent Dermatology Expert to Board - TipRanks

Apr 13, 2026

Apr 13, 2026

Palvella Therapeutics Appoints Dr. John D. Doux to Board of Directors to Advance Rare Disease Initiatives - Quiver Quantitative

Apr 13, 2026

Apr 13, 2026

Palvella Therapeutics appoints John Doux to board of directors - Investing.com

Apr 13, 2026

Apr 13, 2026

Form 8-KCurrent report - ADVFN

Apr 13, 2026

Apr 11, 2026

Palvella Therapeutics (PVLA) price target increased by 15.78% to 224.97 - MSN

Apr 11, 2026

Apr 10, 2026

Volatility Watch: How does Palvella Therapeutics Inc compare to its peersEarnings Growth Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn

Apr 10, 2026

Apr 08, 2026

Palvella appoints McDonough as SVP of market access, patient services - MSN

Apr 08, 2026

Apr 08, 2026

PVLA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 08, 2026

Apr 08, 2026

Will Palvella Therapeutics (PVLA) Stock Miss Expectations | Price at $118.55, Down 1.24%Community Sell Signals - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 08, 2026

Apr 08, 2026

Palvella Therapeutics, Inc. (PVLA) stock price, news, quote and history - Yahoo Finance Singapore

Apr 08, 2026

Apr 08, 2026

Palvella Reports 2025 Results, Advances QTORIN Drug Pipeline - MyChesCo

Apr 08, 2026

Apr 07, 2026

Latest PVLA NewsPalvella Therapeutics to Present at the TD ... - Stock Titan

Apr 07, 2026